MX363149B - Vacunas de nucleoproteina de la influenza. - Google Patents
Vacunas de nucleoproteina de la influenza.Info
- Publication number
- MX363149B MX363149B MX2015013304A MX2015013304A MX363149B MX 363149 B MX363149 B MX 363149B MX 2015013304 A MX2015013304 A MX 2015013304A MX 2015013304 A MX2015013304 A MX 2015013304A MX 363149 B MX363149 B MX 363149B
- Authority
- MX
- Mexico
- Prior art keywords
- influenza
- vaccines
- influenza nucleoprotein
- variant
- nucleoprotein
- Prior art date
Links
- 206010022000 influenza Diseases 0.000 title abstract 4
- 102000011931 Nucleoproteins Human genes 0.000 title abstract 3
- 108010061100 Nucleoproteins Proteins 0.000 title abstract 3
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 102000037865 fusion proteins Human genes 0.000 abstract 2
- 108020001507 fusion proteins Proteins 0.000 abstract 2
- 101710159767 C4b-binding protein alpha chain Proteins 0.000 abstract 1
- 102100037084 C4b-binding protein alpha chain Human genes 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 230000005847 immunogenicity Effects 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 238000006384 oligomerization reaction Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/11—Orthomyxoviridae, e.g. influenza virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
- C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
- C07K14/16—HIV-1 ; HIV-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
- C07K14/445—Plasmodium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Pulmonology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Mycology (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- AIDS & HIV (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13305320 | 2013-03-18 | ||
| PCT/EP2014/055438 WO2014147087A1 (en) | 2013-03-18 | 2014-03-18 | Influenza nucleoprotein vaccines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015013304A MX2015013304A (es) | 2015-12-15 |
| MX363149B true MX363149B (es) | 2019-03-11 |
Family
ID=48044708
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015013304A MX363149B (es) | 2013-03-18 | 2014-03-18 | Vacunas de nucleoproteina de la influenza. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9243047B2 (enExample) |
| EP (1) | EP2976357B1 (enExample) |
| JP (1) | JP2016520534A (enExample) |
| KR (1) | KR102379951B1 (enExample) |
| CN (2) | CN113307881A (enExample) |
| AU (1) | AU2014234363B2 (enExample) |
| BR (1) | BR112015023738B8 (enExample) |
| CA (1) | CA2901888C (enExample) |
| MX (1) | MX363149B (enExample) |
| RU (1) | RU2662667C2 (enExample) |
| WO (1) | WO2014147087A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112015013387B8 (pt) * | 2012-12-11 | 2023-01-10 | Osivax Sas | Proteínas tipo coiled-coil modificadas possuindo propriedades melhoradas |
| EP3941519A4 (en) * | 2019-03-21 | 2023-01-18 | Georgia State University Research Foundation, Inc. | VIRUS-LIKE PARTICLES AND THEIR USES |
| JP2024532221A (ja) | 2021-08-24 | 2024-09-05 | オシバックス | 免疫原性組成物及びそれらの使用 |
| CA3242433A1 (en) | 2021-12-22 | 2023-06-29 | Osivax | Vaccine compositions and their use |
| AU2023237601A1 (en) | 2022-03-22 | 2024-09-05 | Osivax | Mrna vaccine compositions and their use |
| CN115779079A (zh) * | 2022-10-01 | 2023-03-14 | 中国人民解放军军事科学院军事医学研究院 | 一种可增强与佐剂协同免疫效力的电荷调控型抗原蛋白 |
| CN117659138B (zh) * | 2023-12-25 | 2025-04-08 | 华中农业大学 | 一种流感病毒np蛋白突变体及其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL108915A0 (en) * | 1993-03-18 | 1994-06-24 | Merck & Co Inc | Polynucleotide vaccine against influenza virus |
| WO1999012036A1 (en) * | 1997-09-04 | 1999-03-11 | Stanford University | Reversible immobilization of arginine-tagged moieties on a silicate surface |
| WO2004016283A2 (en) * | 2002-08-14 | 2004-02-26 | Avidis Sa | Heteropolymeric compound comprising a scaffold, an adjuvant and an antigen, and its use |
| CN1867588A (zh) * | 2003-08-12 | 2006-11-22 | 阿维迪斯公司 | 包含c4bp核心蛋白质和单体抗原的产品及其用途 |
| EP1795540A1 (en) * | 2005-11-30 | 2007-06-13 | Imaxio | Multimeric complexes of antigens and an adjuvant |
| EP2060586A1 (en) * | 2007-11-14 | 2009-05-20 | PharmaSurgics in Sweden AB | New synthetic arginine substituted peptides and their use |
| GB0918154D0 (en) * | 2009-10-16 | 2009-12-02 | Isis Innovation | Mycobacterial vaccines |
| BR112015013387B8 (pt) * | 2012-12-11 | 2023-01-10 | Osivax Sas | Proteínas tipo coiled-coil modificadas possuindo propriedades melhoradas |
-
2014
- 2014-03-18 WO PCT/EP2014/055438 patent/WO2014147087A1/en not_active Ceased
- 2014-03-18 CA CA2901888A patent/CA2901888C/en active Active
- 2014-03-18 CN CN202110430609.2A patent/CN113307881A/zh active Pending
- 2014-03-18 CN CN201480013364.1A patent/CN105143251B/zh not_active Expired - Fee Related
- 2014-03-18 KR KR1020157029403A patent/KR102379951B1/ko active Active
- 2014-03-18 AU AU2014234363A patent/AU2014234363B2/en active Active
- 2014-03-18 MX MX2015013304A patent/MX363149B/es unknown
- 2014-03-18 JP JP2016503642A patent/JP2016520534A/ja active Pending
- 2014-03-18 BR BR112015023738A patent/BR112015023738B8/pt not_active IP Right Cessation
- 2014-03-18 RU RU2015140603A patent/RU2662667C2/ru active
- 2014-03-18 EP EP14710594.4A patent/EP2976357B1/en active Active
- 2014-12-15 US US14/570,155 patent/US9243047B2/en active Active
-
2015
- 2015-12-21 US US14/975,918 patent/US9963490B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20150131292A (ko) | 2015-11-24 |
| CN105143251B (zh) | 2021-05-11 |
| BR112015023738B8 (pt) | 2023-02-14 |
| BR112015023738A2 (pt) | 2017-11-21 |
| US9243047B2 (en) | 2016-01-26 |
| CA2901888A1 (en) | 2014-09-25 |
| EP2976357B1 (en) | 2018-10-17 |
| AU2014234363A1 (en) | 2015-09-03 |
| CA2901888C (en) | 2023-06-20 |
| RU2662667C2 (ru) | 2018-07-26 |
| RU2015140603A (ru) | 2017-04-21 |
| US9963490B2 (en) | 2018-05-08 |
| US20150098958A1 (en) | 2015-04-09 |
| EP2976357A1 (en) | 2016-01-27 |
| KR102379951B1 (ko) | 2022-03-31 |
| WO2014147087A1 (en) | 2014-09-25 |
| US20160215032A1 (en) | 2016-07-28 |
| MX2015013304A (es) | 2015-12-15 |
| JP2016520534A (ja) | 2016-07-14 |
| CN105143251A (zh) | 2015-12-09 |
| CN113307881A (zh) | 2021-08-27 |
| BR112015023738B1 (pt) | 2023-01-10 |
| AU2014234363B2 (en) | 2018-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015013304A (es) | Vacunas de nucleoproteina de la influenza. | |
| EA201591287A1 (ru) | Вакцины, содержащие стабилизированные тримеры оболочки вируса иммунодефицита человека, и способы их применения | |
| WO2013106834A3 (en) | Immunogenic wt-1 peptides and methods of use thereof | |
| BR112017008165A2 (pt) | anticorpos de domínio único direcionados contra antígenos intracelulares | |
| WO2015052543A3 (en) | Malaria vaccination | |
| MX2013008836A (es) | Moleculas de acido nucleico que codifican novedosos antigenos de herpes, vacunas que las comprenden y metodos para su uso. | |
| MX387985B (es) | Particulas tipo virus modificadas de cmv. | |
| MX2018010483A (es) | Inmunogenos para vacunacion contra vih. | |
| WO2016019134A8 (en) | Flagellin-based agents and uses including effective vaccination | |
| UY36006A (es) | Construcciones de proteína uspa2 y usos de las mismas. | |
| EA201391515A1 (ru) | Инактивированная вакцина вируса денге | |
| EA201691348A1 (ru) | Однофлаконные вакцинные составы | |
| MX344103B (es) | Vacunas de virus herpes vectorizado con virus de enfermedad de newcastle. | |
| WO2015020913A3 (en) | Influenza hemagglutinin proteins and methods of thereof | |
| TN2014000518A1 (en) | Reassortant btv and ahsv vaccines | |
| EP2873423A3 (en) | Soluble hiv-1 envelope glycoprotein trimers | |
| EP3939604A3 (en) | Influenza hemagglutinin protein vaccines | |
| MX382530B (es) | Vacunas inactivadas contra la influenza canina, metodos para elaborarlas y sus usos. | |
| MX355759B (es) | Peptidos topk y vacunas que incluyen los mismos. | |
| WO2014140166A3 (en) | Vaccine | |
| PH12017501100B1 (en) | Recombinant swinepox virus and vaccines | |
| MX2019007924A (es) | Vacunas contra la influenza. | |
| BR112012029633A8 (pt) | Vetores do parapoxvírus contendo antígeno do vírus da raiva. | |
| IN2014DN09445A (enExample) | ||
| WO2015070207A3 (en) | Ama-1 epitopes, antibodies, compositions, and methods of making and using the same |